Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Breast Cancer

• Publication date

  2021-08-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12282-021-01282-5PMID 34346034
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

  2021cited by this paper
• Cell Cycle and DNA Repair Regulation in the Damage Response: Protein Phosphatases Take Over the Reins

  2020cited by this paper
• Decreased ER dependency after acquired resistance to CDK4/6 inhibitors

  2020cited by this paper
• Inhibition of CD4/CDK6 enhances radiosensitivity of HPV negative head and neck squamous cell carcinomas.

  2019cited by this paper
• The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer

  2019cited by this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2019cited by this paper
• The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

  2019cited by this paper
• MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer

  2018cited by this paper
• CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest.

  2018cited by this paper
• Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition

  2018cited by this paper
• Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

  2018cited by this paper
• Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer

  2018cited by this paper
• Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors

  2017cited by this paper
• MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

  2017cited by this paper
• Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.

  2017cited by this paper
• MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

  2017cited by this paper
• PARP inhibitors: Synthetic lethality in the clinic

  2017cited by this paper
• Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

  2016cited by this paper
• Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

  2016cited by this paper
• Palbociclib and Letrozole in Advanced Breast Cancer.

  2016cited by this paper
• Mechanisms of aromatase inhibitor resistance

  2015cited by this paper
• Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

  2015cited by this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2015cited by this paper
• Cisplatin in cancer therapy: molecular mechanisms of action.

  2014cited by this paper
• Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.

  2014cited by this paper
• 53BP1: pro choice in DNA repair.

  2014cited by this paper
• Frequencies of mutagenic translesion DNA synthesis over cisplatin-guanine intra-strand crosslinks in lacZ plasmids propagated in human cells.

  2014cited by this paper
• Estrogen response element-GFP (ERE-GFP) introduced MCF-7 cells demonstrated the coexistence of multiple estrogen-deprivation resistant mechanisms.

  2014cited by this paper
• Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.

  2014cited by this paper
• Cdks, cyclins and CKIs: roles beyond cell cycle regulation

  2013cited by this paper
• Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

  2010cited by this paper
• Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival

  2009cited by this paper
• Breast cancer susceptibility: current knowledge and implications for genetic counselling

  2009cited by this paper
• "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

  2008cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer.

  1998cited by this paper

• Is it feasible for CDKs inhibitors to herald a new era in tackling the low sensitivity and drug resistance associated with PARP inhibitors?

  2026cites this paper
• Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer

  2025cites this paper
• Preclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review

  2024cites this paper
• Seize the engine: Emerging cell cycle targets in breast cancer

  2024cites this paper
• Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast Cancer.

  2024cites this paper
• Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer

  2024cites this paper